Pfizer's (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025.

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade. However, the outlook appears brighter, thanks to its strong pipeline of drugs currently in development. Much of the negative sentiment seems to be already reflected in its depressed share price. Recently, the company’s forward P/E ratio stood at 8.3, which is noticeably lower than its five-year average of 10.2.

Pfizer Inc. (NYSE:PFE) reported mixed earnings in the first quarter of 2025. The company posted revenue of $13.7 billion, down 8% on a YoY basis. The revenue also missed analysts’ estimates of $335.8 million; however, its EPS of $0.92 beat the consensus by $0.25. The company noted that its emphasis on operational efficiency and financial discipline has been contributing positively to its bottom line. It further stated that performance is currently tracking toward the higher end of its 2025 adjusted diluted EPS guidance range.

Pfizer Inc. (NYSE:PFE)’s strong balance sheet allowed it to return $2.4 billion to shareholders through dividends during the quarter. The company has raised its payouts for 15 years in a row. It offers a quarterly dividend of $0.43 per share and has a dividend yield of 7.03%, as of July 17.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Industrial Dividend Stocks to Buy Right Now and 10 Best Passive Income Stocks to Buy Now.

Disclosure: None.